Ann: Paradigm AGM Presentation, page-97

Hi Zenox.
Bit perplexed here if it is LNA043 you are talking about, and also whether you are talking about us getting over the line, or getting over the line before LNA043 might. I think there is a difference between the two.

You can see the summary of the early LNA043 trial HERE with some choice snippets copied below....

And just add onto the safety and efficacy profile other things like patient conveience (injection into knee, vs subQ at home with auto injector), local knee treatement vs systemic (iPPS lay also have prophylactic effects on the non OA knee, and/or you can treat 2 knees for the price of one, plus other joints in the body). It appears to focus mainly on cartilage with not much effect on pain, inflammation, BML etc. and is a P2b with a 2025 completeion date. Intriguing that thier primary endpoint is cartilage volume and KOOS pain where I thought the FDA was pretty clear about clinical outcomes (WOMAC pain and function) being the measure of success, not a structural biomarker like cartilage volume which means pretty much nothing if the patient is in the same pain and impeded function.

Then even if LNA043 does get through, and does so before PAR, is that really an issue with such a big market and the sorts of valuations possible with just 10% of that.

I think we are best to concentrate on getting through and not focussing on beating others to it. I'm pretty sure that has been the MO of the company all along (eg. delaying and pivoting 008) and this has caused some angst for investors wanting a quick return. But better to get it through than rush and fail. I believe provisional approval is another exampe of taking the time needed to maximise its chance of approval, than trying to rush it.